Ross Camidge, MD on The Concept of Overall Survival and Crossover in Randomized Phase III Studies @CUCancerCenter

Ross Camidge, MD on The Concept of Overall Survival and Crossover in Randomized Phase III Studies @CUCancerCenter

User Photo
Cancer-News

4 months
67 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 1
Category:
Description:

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer.

Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Up Next Autoplay
>